Ethyl-EPA Treatment of Prodromal Patients

Yale University

Status and phase: Completed; Phase 3; Phase 2

Conditions: Schizophrenia Prodrome

Treatments: Drug: ethyl-eicosapentaenoic acid

Study type: Interventional

Funder types: Other

Identifiers

NCT00634361

LA01.03.0011

Details and patient eligibility

About

This is an open-label trial of an omega-3 fatty acid for symptoms of the schizophrenia prodrome.

Enrollment: 7 patients

Sex: All

Ages: 14 to 35 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• meets criteria for schizophrenia prodrome

Exclusion criteria

• any lifetime antipsychotic treatment

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

7 participants in 1 patient group

A

Experimental group

Treatment:

Drug: ethyl-eicosapentaenoic acid